Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Renal MRI and Advanced Biochemical Markers to Predict Progression in DKD Patients Treated With SGLT2i (PERSONALISEDKD)

16 de noviembre de 2026 actualizado por: Mario Negri Institute for Pharmacological Research

Multiparametric Renal MRI and Advanced Biochemical Markers to Predict Progression of Diabetic Kidney Disease in Patients Treated With SGLT2 Inhibitors: a Longitudinal Multicentre Clinical Study

This is a multicentre and multi-national non-pharmacological, uncontrolled interventional study conducted in a clinical practice setting in DKD patients with CKD stages G1 to G3 with moderate or severe risk of renal function decline in chronic treatment with SGLT2i.

The main aim of the study is to assess the independent role of baseline individual mpMRI markers (hemodynamic, oxygenation, microstructure, perfusion, and fat fraction) and biochemical markers of MMP-related pathways (MMP-10 and TIMP-1) in the prediction of chronic eGFR decline over 18 months in the above mentioned patients who are on chronic SGLT2i therapy.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

Recent years have seen an exponential increase in the incidence and prevalence of chronic kidney disease (CKD). Diabetes Mellitus is the leading cause of CKD. Diabetic kidney disease (DKD) is clinically defined by the presence of reduced kidney function and/or increased albuminuria for at least three months in patients with diabetes. However, not all patients with diabetes develop DKD and not all patients with DKD follow the same trajectory. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have recently shown significant nephroprotective benefits, making them a first-line therapy in DKD. Although the mechanisms underlying SGLT2i nephroprotection are not fully understood, preliminary data suggest a long-term benefit on metabolic, haemodynamics, and/or kidney injury pathways. SGLT2i have also been shown to be nephroprotective in mouse models, attenuating renal fibrosis in diabetes. These promising results highlight the potential of SGLT2i to avert severe CKD-related events through early intervention, particularly in patients at higher risk of progression. However, clinical, and genetic factors may influence response to SGLT2i in patients with comorbid conditions and already receiving antidiabetic and antihypertensive drugs. Therefore, within a personalised medicine approach, it would be essential to early identify DKD patients with fast progressive decline in renal function, associated with increased morbidity and mortality, who may benefit the most from SGLT2i therapy. To achieve this, biomarkers with heightened specificity and sensitivity to disease progression and response to treatment are urgently needed.

Renal multiparametric MRI (mpMRI) has recently shown great potential to investigate renal structure, microstructure, and function, facilitating the diagnosis and monitoring of CKD progression and response to treatment. Recent studies showed the ability of decreased renal blood flow - assessed by arterial spin labelling (ASL) MRI - in detecting subclinical renal involvement in patients with type 2 diabetes. Blood oxygenation level dependent (BOLD)-MRI showed an acute effect on renal cortical oxygenation in response to SGLT2i treatment in type I diabetic patients with albuminuria. mpMRI shows potential to investigate and quantify renal and perirenal adipose tissue (fat fraction), that is thought to play a significant role on the renal involvement in diabetes and obesity. mpMRI has also shown its ability to monitor the effects of SGLT2i in type 2 diabetes.

Moreover, the hallmark of DKD pathogenesis is excessive accumulation of extracellular matrix (ECM) leading to thickening of the glomerular and tubular basement membranes, followed by mesangial expansion, sclerosis, and tubulointerstitial fibrosis. Dysregulated balance between levels of matrix metalloproteases (MMPs, involved in ECM degradation and hydrolysis) and their tissue inhibitors (TIMP) has been found in DKD patients, and altered serum and urine TIMP-1 levels have been linked with worsening glomerular lesions. MMP-10 null diabetic mice presented fewer mesangial expansion, renal macrophage infiltration and renal function impairment. These findings may support a deleterious kidney effect of MMP-10 in DKD.

To confirm and expand these single-centre findings, a more in-depth analysis of pathogenic mechanisms and a more accurate risk stratification are required in order to personalise the clinical management of DKD.

The PERSONALISE-DKD clinical study aims to use advanced biochemical and imaging biomarkers to characterize DKD patients at moderate or severe risk of renal disease progression who may get the greatest benefit from future clinical trials and targeted healthcare management interventions, potentially contributing to a change in the current clinical approach to a disease that represents the leading cause of advanced CKD.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

100

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Denmark
      • Aarhus, Denmark, Dinamarca
        • Department of Renal Medicine - Aarhus University Hospital
        • Contacto:
    • Spain
      • Pamplona, Spain, España
        • Nephrology Department - Clínica Universidad de Navarra
        • Contacto:
    • BG
      • Ranica, BG, Italia, 24020
        • Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria (to be eligible to participate in this trial, an individual must meet all the following criteria):

  1. male and female subjects aged ≥18 years at time of screening;
  2. written informed consent prior to any study specific procedures;
  3. type 2 Diabetes Mellitus with DKD;
  4. CKD stage G1 to G3 (eGFR>30 ml/min calculated by the creatinine CKD-EPI 2009 equation) with moderate or severe risk of renal disease progression (according to KDIGO 2024 CKD guidelines, G1 and G2 with albuminuria >300 mg/g, G3a with albuminuria >30 mg/g, and G3b independently of albuminuria levels);
  5. ongoing SGLT2i treatment (e.g. canagliflozin, empagliflozin or dapagliflozin) for at least 1 month and no longer than 1 year, and stable RAS inhibitor therapy with ACE inhibitors and/or ARBs (or without RAS inhibitors in patients with specific contraindications for this medication) (Group 1) or SGLT2i-naïve subjects who have been prescribed this therapy as part of routine clinical practice prior to enrollment (Group 2).

Exclusion Criteria (an individual who meets any of the following criteria will be excluded from participation in this trial):

  1. Uncontrolled diabetes (glycated hemoglobin (A1C) > 8%; 64 mmol/mol);
  2. Contraindications to MRI including claustrophobia, pregnancy or breastfeeding, cardiac pacemakers, or other MRI-incompatible prostheses, or inability to undergo MRI;
  3. Any chronic clinical condition (e.g. history of malignancy) other than CKD and related complications that may compromise study completion or affect data interpretation;
  4. Non-diabetic CKD: CKD highly suspected to be related with a different renal condition other than Diabetes Mellitus as the cause of CKD (i.e. glomerular disease, tubulo-interstitial nephritis, microangiopathic thrombotic disease, renovascular/ischemic kidney disease, etc);
  5. Active systemic autoimmune diseases;
  6. Concomitant treatment with steroids or any other immunosuppressive agent;
  7. Chronic heart failure class III-IV according to New York Heart Association (NYHA) classification at the screening visit;
  8. Intention to become pregnant within the next 2 years (female patients);
  9. Drug or alcohol abuse.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Patients

Adult Diabetic Kidney Disease (DKD) patients with CKD stages G1 to G3 at moderate or severe risk of renal disease progression, receiving ongoing SGLT2i treatment (e.g. canagliflozin, empagliflozin or dapagliflozin) for at least 1 month and no longer than 1 year, and stable RAS inhibitor therapy with ACE inhibitors and/or ARBs (or without RAS inhibitors in patients with specific contraindications for this medication).

Multiparametric non-contrast enhanced renal MRI and biochemical analysis to investigate MMP-related pathways (MMP-10 and TIMP-1 serum levels)

Experimental: SGLT2i-naïve patients

Adult patients with diabetic kidney disease (DKD), CKD stages G1-G3, at moderate or severe risk of renal disease progression, who are SGLT2i-naïve at the time of screening and have been prescribed SGLT2i therapy as part of routine clinical practice prior to study enrollment.

Multiparametric non-contrast enhanced renal MRI and biochemical analysis to investigate MMP-related pathways (MMP-10 and TIMP-1 serum levels)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Estimated glomerular filtration rate (eGFR)
Periodo de tiempo: At day 0, at 1 month and at 18 months

EGFR estimation by CKD-EPI and EKFC equations (ml/min)

At day 0, at 1 month and at 18 months
Matrix metalloproteases (MMPs) and their tissue inhibitors (TIMP)
Periodo de tiempo: At day 0, at 1 month and at 18 months

Serum levels of MMP-10 and TIMP-1 will be assessed in blood samples by commercial ELISA kits, according to the manufacturer's instructions (pg/ml)

At day 0, at 1 month and at 18 months
Multiparametric kidney MRI
Periodo de tiempo: At day 0, at 1 month and at 18 months

Total kidney, cortical and medullary volumes (in mL)

At day 0, at 1 month and at 18 months
Multiparametric kidney MRI
Periodo de tiempo: At day 0, at 1 month and at 18 months

Renal tissue oxygenation obtained by measuring the R2* relaxation rate (in 1/ms)

At day 0, at 1 month and at 18 months
Multiparametric kidney MRI
Periodo de tiempo: At day 0, at 1 month and at 18 months

Apparent diffusion coefficient (in cm2/s)

At day 0, at 1 month and at 18 months
Multiparametric kidney MRI
Periodo de tiempo: At day 0, at 1 month and at 18 months

Renal tissue perfusion (in mL/100mL/min)

At day 0, at 1 month and at 18 months
Multiparametric kidney MRI
Periodo de tiempo: At day 0, at 1 month and at 18 months

Renal blood flow (in mL/min)

At day 0, at 1 month and at 18 months
Multiparametric kidney MRI
Periodo de tiempo: At day 0, at 1 month and at 18 months

T1 and T2 relaxation times (in ms)

At day 0, at 1 month and at 18 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Director de estudio: Giuseppe Remuzzi, M.D., Istituto Di Ricerche Farmacologiche Mario Negri

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

1 de abril de 2028

Finalización del estudio (Estimado)

1 de abril de 2028

Fechas de registro del estudio

Enviado por primera vez

25 de noviembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

25 de noviembre de 2025

Publicado por primera vez (Actual)

8 de diciembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • PERSONALISE-DKD

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .